COMPOSITIONS AND POPULATIONS OF CELLS OBTAINED FROM THE UMBILICAL CORD AND METHODS OF PRODUCING THE SAME

• US 20090280093A1
• Filed: 02/27/2007
• Published: 11/12/2009
• Est. Priority Date: 03/01/2006
• Status: Abandoned Application

• Current Assignee: The Regenerative Medicine Institute
• Original Assignee: The Regenerative Medicine Institute
• Inventors: Friedlander, Hyman
• Application Number:
  US12/280,566
• Publication Number:
  US 20090280093A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: C12N 2501/70 Enzymes
• CPC Class Codes: C12N 2533/90 Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0647 Haematopoietic stem cells; Uncommitted or multipotent progenitors
• CPC Class Codes: C12N 5/0668 Mesenchymal stem cells from other natural sources
• CPC Class Codes: C12N 5/0692 Stem cells; Progenitor cells; Precursor cells

Abstract

The present invention relates to populations and compositions of stem and progenitor cells derived from the umbilical cord, and methods of obtaining the same. In some embodiments, one or more entire umbilical cords or sections thereof are subjected to a process where a cell population is derived without prior removal of any blood vessel. The population may be derived using mechanical and chemical means. The presently disclosed process may be applied to a single umbilical cord or to a plurality of umbilical cords, for example, as a batch process. Optionally, this process includes removing some or all cord blood before deriving the population. In some embodiments, presently disclosed cell populations include mesenchymal stem cells derived from Wharton'"'"'s jelly and endothelial progenitor cells derived from a wall of a blood vessel of an umbilical cord. Optionally, the cell population includes stem cells derived from cord blood. The presently disclosed cell populations and compositions may be banked and/or used in a number of clinical or other applications. Exemplary applications include but are not limited to applications related to regenerative medicine, for screening compounds, for research, and for gene therapy.

Claims

1-61. -61. (canceled)

62. ) A method of deriving a population of cells, the method comprising:

a) obtaining one or more umbilical cords, each said umbilical cord comprising a respective at least one or more umbilical cord blood vessels and respective umbilical cord matrix;

or possibly a number of cords for batch production, or possibly a fraction of a cord;

b) for each said umbilical cord, mechanically disrupting at least a portion of a respective said umbilical cord blood vessel and at least a portion of respective said umbilical cord matrix to produce a mixture including umbilical cord blood vessel matter and umbilical cord matrix matter; and

c) deriving the population of cells including umbilical cord matrix-derived cells and umbilical cord blood vessel-derived cells from said mixture;

d) The method may include chopping said cord or more umbilical cords into a plurality of small pieces;

The method includes the possibility of forming a paste-like material from the cord or cords and possible enzymatic extraction, deriving said population from said paste-like material. The method may also include a plurality of said umbilical cords within a vessel and subjected to a batch process including at least one of said disrupting and enzymatic extraction and said deriving within said vessel.

63. ) The method of claim 62, further comprising cryopreserving at least a portion of said population of cells.

64. ) The method of claim 63, further comprising the steps of thawing said cryopreserved cells and administering a therapeutic agent comprising said thawed cells to a patient in need thereof.

65. ) The method of claim 62, further comprising the step of charging a fee.

66. ) The method of claim 62, further comprising the step of culturing the population of cells, and/or activation with or without purification, or without any culturing or activation ex vivo

67. ) A population of cells derived by any of the methods of claim 62. The said population of cells may have one or more of combinations of the following surface markers:

SH2, CD31, CD45, CD90, VEGFR-2, CD44, CD13, CD105, ABCG2, CD34, CD133, C117, CD135, CXCR4, VE-Cadherin, MAC-1, CD11, CD14, CD56, Tie-2s. The said population may comprise of one or more of the following progenitors;

Hematopoietic, mesenchymal, endothelial, pluripotent stem cells.

68. ) A cell-based therapeutic agent comprising:

a) the population of cells of claim 67; and

b) a pharmaceutically acceptable carrier.

70. ) The method of claim 62, further comprising administering a therapeutic agent, either by i.v administration or by intra organ injection, or by other methods, comprising said derived population of cells to a patient in need thereof, such as for treatment of a disease associated with biological processes selected from the group of processes consisting of cardiac ischemia, osteoporosis, chronic wounds, diabetes, neural degenerative diseases, neural injuries, bone or cartilage injuries, ablated bone marrow, graft versus host disease, anemia, liver diseases, hair growth, teeth growth, retinal disease or injuries, eye diseases or injuries, car injuries or diseases muscle degeneration or injury and skin treatments and any disease or condition that is treatable by tissue regeneration.

72. ) The method of claim 62, wherein the patient is in need of a cosmetic treatment or therapy selected from the group of cosmetic therapies consisting of filling of skin wrinkles, supporting organs, supporting surgical procedures, treating burns, cosmetic skin treatment, and treating wounds. The combination between the donor and recipient of the cells of said derived cell population is either autologous or allogeneic.

73. ) The population of cells of claim 67, wherein a ratio between a number of said mesenchymal stem cells and said hematopoeitic stem cells and said endothelial progenitor cells within the population is substantially equal to the naturally occurring ratio within the umbilical cords.

74. ) Utilizing the population of cells of claim 67, for screening compounds, for research, and for gene therapy.

69. ) A population of cells comprising stem cells and progenitor cells isolated from the umbilical cord tissues by a method that consists essentially of mechanical and enzymatic extraction without prior removal of any blood vessel, and the method for preserving these cell populations.

71. ) The combination between the donor and recipient of the cells of said derived cell population is either autologous or allogeneic.